ACI’s 8th Annual Summit on Life Sciences IP Due Diligence returns to Boston this December.
Delivering critical insights and strategies, this year’s summit will help corporate, and IP counsel navigate today’s rapidly evolving legal and regulatory landscape. Join leading in-house counsel, IP experts, and industry leaders as they share best practices for conducting thorough due diligence, identifying hidden risks, and strengthening the value and protection of life sciences IP assets.
Stay ahead of regulatory changes, patent challenges, and deal complexities — ensuring your IP strategies can withstand heightened scrutiny and futureproof your portfolio.
Past Attending Organizations
- AMRI
- Allergan plc
- AtriCure Inc
- Azurity Pharmaceuticals Inc
- BONWRx
- Beck & Thomas
- Biogen
- Blaze Bioscience Inc
- BlueRock Therapeutics
- Boehringer Ingelheim International GmbH
- Boston University (CARB-X)
- Brammer Bio
- Brinks Gilson & Lione
- Centre for Drug Research and Development
“Unique high level sessions, good mix of in-house and outside counsel.”
“Hearing from professionals involved in due diligence on a daily basis was very informative.”
“Great panels, lots of diversity of practice, and lots of seasoned practitioners.”
“The design of the event brought us all together along with room intimacy.”
Sponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]
